» Articles » PMID: 35493151

Recent Advances in Functionalized Upconversion Nanoparticles for Light-activated Tumor Therapy

Overview
Journal RSC Adv
Specialty Chemistry
Date 2022 May 2
PMID 35493151
Authors
Affiliations
Soon will be listed here.
Abstract

Upconversion nanoparticles (UCNPs) are a class of optical nanocrystals doped with lanthanide ions that offer great promise for applications in controllable tumor therapy. In recent years, UCNPs have become an important tool for studying the treatment of various malignant and nonmalignant cutaneous diseases. UCNPs convert near-infrared (NIR) radiation into shorter-wavelength visible and ultraviolet (UV) radiation, which is much better than conventional UV activated tumor therapy as strong UV-light can be damaging to healthy surrounding tissue. Moreover, UV light generally does not penetrate deeply into the skin, an issue that UCNPs can now address. However, the current studies are still in the early stage of research, with a long way to go before clinical implementation. In this paper, we systematically analysed recent advances in light-activated tumor therapy using functionalized UCNPs. We summarized the purpose and mechanism of UCNP-based photodynamic therapy (PDT), gene therapy, immunotherapy, chemo-therapy and integrated therapy. We believe the creation of functional materials based on UCNPs will offer superior performance and enable innovative applications, increasing the scope and opportunities for cancer therapy in the future.

Citing Articles

Comparison of the Differences between Two-Photon Excitation, Upconversion, and Conventional Photodynamic Therapy on Cancers in In Vitro and In Vivo Studies.

Xu C, Law S, Leung A Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931331 PMC: 11206628. DOI: 10.3390/ph17060663.


Temoporfin-Conjugated PEGylated Poly(,-dimethylacrylamide)-Coated Upconversion Colloid for NIR-Induced Photodynamic Therapy of Pancreatic Cancer.

Shapoval O, Patsula V, Vetvicka D, Engstova H, Oleksa V, Kabesova M Biomacromolecules. 2024; 25(9):5771-5785.

PMID: 38888278 PMC: 11388470. DOI: 10.1021/acs.biomac.4c00317.


Current State of Human Gene Therapy: Approved Products and Vectors.

Shchaslyvyi A, Antonenko S, Tesliuk M, Telegeev G Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895887 PMC: 10609992. DOI: 10.3390/ph16101416.


Recent advances in diverse nanosystems for nitric oxide delivery in cancer therapy.

Gao D, Asghar S, Hu R, Chen S, Niu R, Liu J Acta Pharm Sin B. 2023; 13(4):1498-1521.

PMID: 37139410 PMC: 10149905. DOI: 10.1016/j.apsb.2022.11.016.


Light-activated nanomaterials for tumor immunotherapy.

Wang F, Duan H, Xu W, Sheng G, Sun Z, Chu H Front Chem. 2022; 10:1031811.

PMID: 36277335 PMC: 9585221. DOI: 10.3389/fchem.2022.1031811.


References
1.
Gnach A, Lipinski T, Bednarkiewicz A, Rybka J, Capobianco J . Upconverting nanoparticles: assessing the toxicity. Chem Soc Rev. 2014; 44(6):1561-84. DOI: 10.1039/c4cs00177j. View

2.
Xia T, Kovochich M, Liong M, Meng H, Kabehie S, George S . Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano. 2009; 3(10):3273-86. PMC: 3900639. DOI: 10.1021/nn900918w. View

3.
Qiao J, Fu Y . Cytokines that target immune killer cells against tumors. Cell Mol Immunol. 2020; 17(7):722-727. PMC: 7331613. DOI: 10.1038/s41423-020-0481-0. View

4.
Carling C, Boyer J, Branda N . Remote-control photoswitching using NIR light. J Am Chem Soc. 2009; 131(31):10838-9. DOI: 10.1021/ja904746s. View

5.
Jiang S, Zhang Y, Lim K, Sim E, Ye L . NIR-to-visible upconversion nanoparticles for fluorescent labeling and targeted delivery of siRNA. Nanotechnology. 2009; 20(15):155101. DOI: 10.1088/0957-4484/20/15/155101. View